Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions

Recruiting

Phase 2

NivolumabPhase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT06561087

Conditions

Premalignant Lesion

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Nivolumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-10. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2025-08-06.